Acute circulatory failure secondary to myocardial infarction.
D000804:Angiotensin II / Q000627:therapeutic use; D001794:Blood Pressure; D002245:Carbon Dioxide / Q000097:blood; D002496:Central Venous Pressure; D004809:Ephedrine / Q000627:therapeutic use; D006439:Hemodynamics; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007263:Infusions, Parenteral; D008680:Metaraminol / Q000627:therapeutic use; D008729:Methoxamine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications*; D009638:Norepinephrine / Q000627:therapeutic use; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D010656:Phenylephrine / Q000627:therapeutic use; D012039:Regional Blood Flow; D012770:Shock, Cardiogenic / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy
D000804:Angiotensin II; D002245:Carbon Dioxide; D010656:Phenylephrine; D008680:Metaraminol; D004809:Ephedrine; D008729:Methoxamine; D010100:Oxygen; D009638:Norepinephrine